Carmen Mannucci
Gioacchino Calapai
Sebastiano Gangemi- 1Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
- 2School and Division of Allergy and Clinical Immunology, Department of Experimental Medicine, University of Messina, Messina, Italy
A Commentary on
Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD
by Azizieh, F.Y., Shehab, D., Al Jarallah, K., Mojiminiyi, O., Gupta, R., and Raghupathy, R. (2019). J. Inflamm. Res. 12, 99–108. doi: 10.2147/JIR.S203590
Osteoporosis, one of the most important conditions associated with aging, is characterized by low bone mass and micro-architectural bone tissue deterioration, due to bone resorption and bone formation imbalance (1, 2). The immune system contributes to postmenopausal osteoporosis through the pro-inflammatory cytokine modulation of osteoblast and osteoclast activity (3–6). It has also been suggested that adipose tissue influences the regulation of bone metabolism, contributing to osteoporosis pathophysiology, thanks to the independent endocrine and paracrine activity associated with adipokines production (7, 8).
We have read with great interest the article by Azizieh et al. (8), aimed at measuring circulatory levels of several cytokines (IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, TNF-α, IFN-γ, TGF-β), adipokines, bone turnover marker density, and estradiol levels in postmenopausal women with normal and low bone mineral density (BMD). Results showed that circulatory cytokine levels were comparable in women with low or normal BMD. Women with low BMD, showed statistically significant higher median circulatory levels of adipokines compared to women with normal BMD. Moreover, while the C-terminal cross-linking telopeptide of type I collagen (CTX) levels were not different between the two groups, the procollagen type I N Propeptide (PINP), PINP/CTX ratio, and estradiol levels were significantly lower in women with low BMD. The Adiponectin, PINP, PINP/CTX ratio, and estradiol levels correlated significantly with BMD of the hip and spine (8).
We congratulate the authors for a remarkable study, and agree that the results indicate the possible role of the considered cytokines, adipokines, and bone turnover markers in the pathogenesis of postmenopausal osteoporosis. Here we focus on the role of the IL-31/IL-33 axis.
Interleukin-33 (IL-33) belongs to the IL-1 cytokine family, it is mainly expressed in stromal cells, and upregulated following pro-inflammatory stimulation (9).
IL-33, described as a Th2 cytokine inducer, is considered a traditional cytokine, an “alarmin” and a nuclear factor controlling gene transcription (10). IL-33 has powerful effects on many cell types such as ILC2s (type 2 innate lymphoid cells), mast cells, eosinophils, and Th2 lymphocytes, in particular, IL-33 plays a major role in ILC2 recruitment. IL-33 activates ILC2s via NF-κB and MAPK signaling pathways, causing enhancement of the production of cytokines, chemokines, and peptides (11–15). The responsiveness to these cytokines depends on resident tissues and species, and co-stimulatory cytokines are required for activation (16).
It has also been demonstrated that IL-33 increases its expression after cell death, resulting in the induction of other cytokines including IL-31 (10).
Interleukin-31 (IL-31), belongs to the gp130/IL-6 cytokine family expressed by activated memory CD45RO+ T lymphocytes skewed toward a Th2 phenotype (17–19). Scientific evidence shows a biological role for IL-31 in immunity and inflammation (17, 18). Several cytokines and transcription factors are involved in the development of osteoporosis, and some of them are regulated by IL-31 (18–21). Engagement of the receptor complex results in the activation of Janus kinase and different signaling molecules, including signal transducers and activators of transcription factors, Akt, NF-κB (12, 13, 18), MAPK (17, 18), and the PI3K signaling pathways (19). These pathways are involved both in bone remodeling and inflammation (20, 21).
In our previous studies, based on the IL-31 and IL-33 role in inflammation and bone remodeling (22–24) we evaluated, their involvement in postmenopausal osteoporosis. Measurements of the serum of IL-31 and IL-33 were performed both in women with osteoporosis and healthy women as controls. Osteoporosis was evaluated by BMD measurement expressed as T-score (23).
Our results showed a statistically significant increase of IL-31 serum levels in postmenopausal women with decreased BMD, suggesting a role of IL-31 in osteoporosis. Serum IL-31 levels are not related with the severity of osteoporosis, as indicated by BMD values and/or the presence of fractures (23).
Serum IL-33 levels were significantly lower in postmenopausal osteoporotic patients than non-osteoporotic patients and a correlation between IL-33 and PTH serum levels was also observed (24).
Though the direct effect of IL-33 on osteoclast function or bone resorption is not clear, our results showed that a negative correlation between IL-33 and CTX seems to confirm the inhibition of osteoclast differentiation mediated by IL-33 (24).
The lower levels of IL-33 found in osteoporotic patients agree with several experimental observations showing inhibition of osteoclast differentiation by IL-33 (25–27). It is known that IL-33 inhibits RANKL-dependent osteoclast formation, protecting it from inflammatory bone loss (28, 29). Furthermore, IL-33 inhibits osteoclast differentiation by inducing antiosteoclastogenic cytokines such as IL-10, IL-4, and IFN-γ and granulocyte-macrophage colony-stimulating factor, skewing osteoclast precursors differentiation to alternatively activated macrophage and dendritic cells (25). A RANKL-like action of IL-33 has also been suggested in human osteoclast formation (30). IL-33 pro-resorption effects on bone is weak and highly variable, compared to the strong effect of RANKL, with some types of osteoclast progenitors that differentiate into functional resorbing cells consequent to IL-33 stimulation and other osteoclast progenitor-containing unresponsive populations (31).
IL-31 serum levels increase in aged osteoporotic patients, suggesting a link between bone resorption and cytokine overexpression, that could enhance bone resorption through chemokines and induction of proinflammatory osteoclastogenic cytokines, leading to osteoclast precursors recruitment, differentiation, and activation. Our results suggest a key role of IL-31 in senile osteoporosis but the exact mechanism of action remains unknown. A clear understanding of IL-31 involvement in bone resorption immunopathology can provide more effective strategies for the treatment of senile osteoporosis.
Our data suggest the existence of an IL-31 and IL-33 correlation axis. This is in accordance with other authors that showed an involvement of the IL-33/ST2 axis in the progression of several inflammatory diseases, influencing the generation of Th17, producing IL-31 (32, 33). The high serum level of IL-31 and IL-33 have also been reported in people with inflammatory and autoimmune diseases (33, 34). IL-31 and IL-33 are linked to each other; induction of one cytokine by the other is correlated with disease severity, inflammation, and harmful processes. Data suggest that IL-33/ST2 axis activation can be considered a biomarker of both a Th2/IL-31 and Th17 immune response (10, 34).
Our results can contribute to a better understanding of the mechanisms at the basis of the immune system capacity, that mount osteoclastogenic immune reactions through inflammatory responses, crucial in senile osteoporosis. Moreover, IL-33 could be considered an important bone-protecting cytokine, becoming a target in the prevention and therapy of postmenopausal osteoporosis.
Author Contributions
CM, GC, and SG have contributed equally to the work, and approved the article for publication.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Alejandro P, Constantinescu F. A review of osteoporosis in the older adult: an update. Rheum Dis Clin North Am. (2018) 44:437–51. doi: 10.1016/j.rdc.2018.03.004
2. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. (2011) 377:1276–87. doi: 10.1016/S0140-6736(10)62349-5
3. Malutan AM, Dan M, Nicolae C, Carmen M. Proinflammatory and anti-inflammatory cytokine changes related to menopause. Prz Menopauzalny. (2014) 13:162–8. doi: 10.5114/pm.2014.43818
4. Faienza MF, Ventura A, Marzano F, Cavallo L. Postmenopausal osteoporosis: the role of immune system cells. Clin Dev Immunol. (2013) 2013:575936. doi: 10.1155/2013/657424
5. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol. (2009) 5:667–76. doi: 10.1038/nrrheum.2009.217
6. Pietschmann P, Mechtcheriakova D, Meshcheryakova A, FögerSamwald U, Ellinger I. Immunology of osteoporosis: a mini-review. Gerontology. (2015) 62:128–37. doi: 10.1159/000431091
7. Mohiti-Ardekani J, Soleymani-Salehabadi H, Owlia MB, Mohiti A. Relationships between serum adipocyte hormones (adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients. J Bone Miner Metab. (2014) 32:400–4. doi: 10.1007/s00774-013-0511-4
8. Azizieh FY, Shehab D, Al Jarallah K, Mojiminiyi O, Gupta R, Raghupathy R. Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD. J Inflamm Res. (2019) 12:99–108. doi: 10.2147/JIR.S203590
9. Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. (2016) 16:676–89. doi: 10.1038/nri.2016.95
10. Di Salvo E, Ventura-Spagnolo E, Casciaro M, Navarra M, Gangemi S. IL-33/IL-31 axis: a potential inflammatory pathway. Mediators Inflamm. (2018) 2018:3858032. doi: 10.1155/2018/3858032
11. Karta MR, Broide DH, Doherty TA. Insights into group 2 innate lymphoid cells in human airway disease. Curr Allergy Asthma Rep. (2016) 16:8. doi: 10.1007/s11882-015-0581-6
12. Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. (2008) 19:347–56. doi: 10.1016/j.cytogfr.2008.08.003
13. Cheung PF, Wong CK, Ho AW, Hu S, Chen DP, Lam CW. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol. (2010) 22:453–67. doi: 10.1093/intimm/dxq027
14. Castellani ML, Felaco P, Galzio RJ, Tripodi D, Toniato E, De Lutiis MA, et al. IL-31 a cytokine involved in immunity and inflammation. Int J Immunopathol Pharmacol. (2010) 23:709–13. doi: 10.1177/039463201002300304
15. Klein Wolterink RG, Kleinjan A, van Nimwegen M, Bergen I, de Bruijn M, Levani Y, et al. Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur J Immunol. (2012) 42:1106–16. doi: 10.1002/eji.201142018
16. Kabata H, Moro K, Koyasu S. The group 2 innate lymphoid cell (ILC2) regulatory network and its underlying mechanisms. Immunol Rev. (2018) 286:37–52. doi: 10.1111/imr.12706
17. Dambacher J, Beigel F, Seiderer J, Haller D, Goke B, Auernhammer CJ, et al. Interleukin-31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut. (2007) 56:1257–65. doi: 10.1136/gut.2006.118679
18. Lee CH, Hong CH, Yu WT, Chuang HY, Huang SK, Chen GS, et al. Mechanistic correlations between two hitch biomarkers, cytokine interleukin-31 and neuropeptide beta-endorphin, via STAT3/calcium axis in atopic dermatitis. Br J Dermatol. (2012) 167:794–803. doi: 10.1111/j.1365-2133.2012.11047.x
19. Park K, Park JH, Yang WJ, Lee JJ, Song MJ, Kim HP. Transcriptional activation of the IL31 gene by NFAT and STAT6. J Leukoc Biol. (2012) 91:245–57. doi: 10.1189/jlb.0111020
20. Charles JF, Nakamura MC. Bone and the innate immune system. Curr Osteoporos Rep. (2014) 12:1–8. doi: 10.1007/s11914-014-0195-2
21. O'Brien CA, Gubrij I, Lin SC, Saylorsi LR, Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but Not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem. (1999) 274:19301–8. doi: 10.1074/jbc.274.27.19301
22. Ginaldi L, De Martinis M. Osteoimmunology and Beyond. Curr Med Chem. (2016) 23:3754–74. doi: 10.2174/0929867323666160907162546
23. Ginaldi L, De Martinis M, Ciccarelli F, Saitta S, Imbesi S, Mannucci C, et al. Increased levels of interleukin 31 (IL-31) in osteoporosis. BMC Immunol. (2015) 16:60. doi: 10.1186/s12865-015-0125-9.
24. Ginaldi L, De Martinis M, Saitta S, Sirufo MM, Mannucci C, Casciaro M, et al. Interleukin-33 serum levels in postmenopausal women with osteoporosis. Sci Rep. (2019) 9:3786. doi: 10.1038/s41598-019-40212-6
25. Zaiss MM, Kurowska-Stolarska M, Böhm C, Gary R, Scholtysek C, Stolarski B, et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-α-mediated bone loss. J Immunol. (2011) 186:6097–105. doi: 10.4049/jimmunol.1003487
26. Saleh H, Eeles D, Hodge JM, Nicholson GC, Gu R, Pompolo S, et al. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology. (2011) 152:1911–22. doi: 10.1210/en.2010-1268
27. Keller J, Catala-Lehnen P, Wintges K, Schulze J, Bickert T, Ito W, et al. Transgenic overexpression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochem Biophys Res Commun. (2012) 417:217–22. doi: 10.1016/j.bbrc.2011.11.088
28. Kiyomiya H, Ariyoshi W, Okinaga T, Kaneuji T, Mitsugi S, Sakurai T, et al. IL-33 inhibits RANKL-induced osteoclast formation through the regulation of Blimp-1 and IRF-8 expression. Biochem Biophys Res Commun. (2015) 460:320–6. doi: 10.1016/j.bbrc.2015.03.033
29. Zhu X, Zhao Y, Jiang Y, Qin T, Chen J, Chu X, et al. Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1. Oncotarget. (2017) 8:53366–74. doi: 10.18632/oncotarget.18411
30. Mine Y, Makihira S, Yamaguchi Y, Tanaka H, Nikawa H. Involvement of ERK and p38 MAPK pathways on Interleukin-33-induced RANKL expression in osteoblastic cells. Cell Biol Int. (2014) 38:655–62. doi: 10.1002/cbin.10249
31. Eeles DG, Hodge JM, Singh PP, Schuijers JA, Grills BL, Gillespie MT, et al. Osteoclast formation elicited by interleukin-33 stimulation is dependent upon the type of osteoclast progenitor. Mol Cell Endocrinol. (2015) 399:259–66. doi: 10.1016/j.mce.2014.10.014
32. Vocca L, Di Sano C, Uasuf CG, Sala A, Riccobono L, Gangemi S, et al. IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases. Immunobiology. (2015) 220:954–63. doi: 10.1016/j.imbio.2015.02.005
33. Bonanno A, Gangemi S, La Grutta S, Malizia V, Riccobono L, Colombo P, et al. 25-Hydroxyvitamin D, IL-31, and IL-33 in children with allergic disease of the airways. Mediators Inflamm. (2014) 2014:520241. doi: 10.1155/2014/520241
Keywords: osteoporosis, IL-31, IL-33, IL31/33 axis, post-menopausal osteoporosis, inflammation
Citation: Mannucci C, Calapai G and Gangemi S (2019) Commentary: Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD. Front. Immunol. 10:2666. doi: 10.3389/fimmu.2019.02666
Received: 04 July 2019; Accepted: 28 October 2019;
Published: 14 November 2019.
Edited by:
Annalisa Del Prete, University of Brescia, ItalyReviewed by:
Salvatore Salomone, University of Catania, ItalyEveraldo Attard, University of Malta, Malta
Copyright © 2019 Mannucci, Calapai and Gangemi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Carmen Mannucci, cmannucci@unime.it